Q-omics provides the consensus-scored RPL7AP66 profile across patient tissues and cancer cell-line models. RPL7AP66 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP66 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, RPL7AP66 RNA expression shows 15,311 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where RPL7AP66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP66 survival associations across molecular data types. RPL7AP66 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP66 RNA expression–survival associations across cancer types. High RPL7AP66 expression shows unfavorable associations in ACC, KIRP, UCEC, OV and SARC, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL7AP66 RNA expression.
This table summarizes RPL7AP66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP66 shows lower tumor expression in HNSC and higher tumor expression in KIRP, LIHC, KIRC, CHOL and THCA. The KIRP box plot shows higher RPL7AP66 RNA expression in tumor versus normal tissue (log2 FC = +0.453, t-test p = .005).
This table shows molecular features associated with RPL7AP66 in patient tissues and cancer cell lines. In patient samples, RPL7AP66 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
